from the tape · 8 episodes
AI-powered analysis of the most important technology podcasts. Guest insights, key takeaways, and the signals that matter.
Semaglutide and tirzepatide, two GLP-1-based obesity and diabetes drugs targeting the same pathway, show markedly different NAION (non-arteritic anterior ischemic optic neuropathy) risk profiles, with EMA mandating label updates for semaglutide (~1 additional case/10,000 person-years) while initial head-to-head data showed no signal for tirzepatide. A 2026 pharmacovigilance analysis has complicated this narrative, identifying 28 ischemic optic neuropathy cases with tirzepatide and a reporting odds ratio of 2.60, though this may reflect underreporting or shorter market exposure rather than true elevated risk. The discontinuation calculus remains stark: patients who stop GLP-1 therapy face up to 22% higher cardiovascular risk after two years, forcing clinicians and patients to weigh rare but potentially permanent vision loss against substantial cardioprotective benefits.
Applied Intuition, which provides simulation and validation software to autonomous vehicle and robotics companies, has grown from $207M to approximately $830M in ARR over two years with 85% gross margins, serving 18 of the 20 largest non-Chinese automakers. The $15 billion valuation bets that this tools business will evolve into a platform with the lock-in characteristics required for sustained competitive advantage—but the company has already run through four complete technology stack overhauls in eight years, suggesting the underlying technical foundation may not yet be stable enough to support that platform narrative. Historical precedent for standardizing the software layer for autonomous systems has produced technically functional but commercially marginal outcomes, raising questions about whether Applied Intuition can escape that pattern.